Richard Christopherson has focused on cancer research since his postdoctoral period in the USA where he was a Fellow of the Damon Runyon-Walter Winchell Cancer Fund (1976-78) and then a Special Fellow of the Leukemia Society of America (1978-80). Richard holds a Personal Chair in the School of Molecular and Microbial Biosciences, serves as the Director of the Sydney University Proteome Research Unit (SUPRU), and the Principal Scientific Founder and Chief Scientific Officer (part-time) of a University spin-off company, Medsaic Pty Ltd (www.medsaic.com). His research focuses on elucidation of the mechanisms of action of drugs used to treat leukaemia. His group elucidated the antipurine mechanism of the drug methotrexate used to treat leukaemias and breast cancer. His current research includes investigation of the mechanisms of action of the anticancer drug fludarabine, by identification of proteins that are differentially expressed in drug-treated cells using two-dimensional fluorescence difference gel electrophoresis (DIGE). A CD antibody microarray (DotScan) has been developed that provides extensive surface expression profiles (immunophenotypes) of leukaemias. A clinical trial with 796 leukaemia patients and normal subjects has shown that expression profiles for 82 CD antigens provide sufficient information for diagnosis of common leukaemias without any other information. This technique has been extended to profiling of colorectal cancers using a technique of fluorescence multiplexing. DotScan has been commercialised by Medsaic Pty Ltd at the Australian Technology Park. Richard was the Chair of the organizing committee for the Sydney Cancer Conference 2010 (SCC2010). This conference was held on July 14-16 at the University of Sydney and emphasized Translational Research.
Biography Updated on 12 January 2011